Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMPL-523 DDI with Itraconazole and Rifampin in Healthy Volunteers
NCT05720767Phase 1Completed
- Sponsor
- HUTCHMED
- Start
- Nov 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sovleplenib in lymphoma (2 arms), sponsored by HUTCHMED. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Time of Last Quantifiable Concentration, Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity and 1 more. Started Nov 2022; status: completed.
02
Drugs
sovleplenib
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT05720767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05720767.